US FDA Offers More Advice On Mid-Trial Changes For Pandemic-Impacted Studies
Executive Summary
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
You may also be interested in...
Cancer Trials Should Focus On Collecting Data ‘Strictly Necessary’ For Assessing Efficacy
In journal article, leaders from academia, industry, NCI and FDA propose building upon pandemic-necessitated flexibilities in clinical research, including making it easier for trial participants to access investigational drugs in their own communities and reduced reporting of uninformative adverse events.
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
ANDA Submissions Drop To Start FY 2021, Perhaps Forced Down By COVID-19
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.